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The role of concurrent chemoradiotherapy (CRT) in patients with non-small-cell lung cancer (NSCLC) unsuitable for radical therapy
but who require locoregional treatment has not been defined. The aims of this phase I trial were thus to develop a novel regimen of
weekly chemotherapy concurrent with high-dose palliative RT (40Gy/20 fractions) and assess its tolerability, objective and
symptomatic response rates. Eligible patients had stage I–IIIB NSCLC unsuitable for radical RT or limited stage IV disease, ECOG
PSp1 and required locoregional therapy. Treatment was RT (40Gy/20 fractions/5 per week) and weekly Vinorelbine plus Cisplatin
escalated in six planned dose levels (DLs). At 4 weeks post-RT, patients received two cycles of Cisplatin 80mgm
 2 day
1þVinorelbine 25mgm
 2 days 1, 8, 15. Dose-limiting toxicities (DLTs) were defined in the CRT phase. Disease-related symptoms
were assessed by the Lung Cancer Symptom Scale. In all, 24 patients accrued, stage IIIB (n¼12) and IV disease (n¼10). The highest
administered dose was at DL 4, Vinorelbine 30mgm
 2þCisplatin 20mgm
 2 with DLTs of grade 4 neutropenia in two of three
patients. No grade 3 or 4 nonhaematological toxicities were observed. The overall radiological response rate was 65% (n¼23:
complete response 4% and partial response 61%) and infield FDG-PET responses were seen in 89% (n¼18). There was an
improvement or stabilisation of symptoms and quality of life. Dose level 3, Vinorelbine 25mgm
 2þCisplatin 20mgm
 2,i s
recommended for further assessment. This regimen was tolerable and produced meaningful responses for patients for whom
locoregional control is required, but who are unsuitable for radical CRT.
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The majority of patients with unresectable stage IIIA or IIIB non-
small-cell lung cancer (NSCLC) are precluded from radical curative
chemoradiotherapy (CRT) either due to the presence of extensive
intrathoracic disease, poor performance status or significant
comorbidities. A subgroup who have good performance status,
limited metastatic involvement and require palliation of local
symptoms have been treated with various regimens of high-dose
palliative radiotherapy (HDPR), ranging from 30Gy in 10 fractions
to 42Gy in 15 fractions or equivalent (MRC Lung Cancer Working
Party, 1992; Macbeth et al, 1996; Ball et al, 1997; Plataniotis et al,
2002; Kramer et al, 2003; Sundstrom et al, 2004). High-dose
palliative radiotherapy has been shown to provide an excellent
palliative benefit through the reduction of local symptoms in 80–
90% of patients, and also benefits in terms of global quality of life
(QOL) (Schaafsma and Coy, 2000; Bezjak et al, 2002; Sundstrom
et al, 2004).
A widely utilised alternative to HDPR has been the use of
hypofractionated radiation schedules, which are considerably less
resource and time intensive. However, a large retrospective
analysis (Quddus et al, 2001) as well as randomised studies have
confirmed that, relative to hypofractionated regimens, HDPR in
patients with good performance status provides a greater benefit in
terms of local symptom palliation, global QOL and survival,
possibly in a dose-dependent manner (Simpson et al, 1985; Teo
et al, 1988; Macbeth et al, 1996; Reinfuss et al, 1999; Gaze et al,
2001; Bezjak et al, 2002; Kramer et al, 2003). These observations
though have not been consistent (MRC Lung Cancer Working
Party, 1991; Nestle et al, 2000; Sundstrom et al, 2004).
Can the advances seen for radical CRT be translated to the
HDPR setting, where the dominant competing risk for death is
locoregional disease, that is, thoracic dominant disease? Rando-
mised trials have demonstrated that the addition of platin-based
chemotherapy to radiation is associated with a survival advantage
when either given as induction (Sause et al, 1995; Dillman et al,
1996) or concurrent treatment (Schaake-Koning et al, 1992)
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scompared to radiation alone. It is unclear whether combining
concurrent chemotherapy with HDPR offers an advantage in terms
of response, palliation and survival. Two studies have been
reported exploring this approach, but with hypofractionated
radiation regimens associated with significant toxicities (Jeremic
et al, 1999; Slivano et al, 2000).
Vinorelbine is a vinca alkaloid with activity both as a single
agent and in combination with platinum analogues in patients with
NSCLC (Le Chevalier et al, 1994; Bunn and Kelly, 1998; The Elderly
Lung Cancer Vinorelbine Italian Study Group, 1999). The agent is
also a radiation sensitiser (Edelstein et al, 1996), which has led to
its assessment in combination with platinum analogues and radical
radiotherapy. The radiation and chemotherapy schedules have
varied between studies; however, response rates have ranged from
62.5 to 80.4% (Masters et al, 1998; Hoffman et al, 2002; Vokes et al,
2002; Zatloukal et al, 2004).
The aims of this trial were thus to determine the highest
administered dose of weekly Cisplatin and Vinorelbine combined
with HDPR (40Gy) for patients with good performance status who
were not suitable for radical CRT, assess the efficacy of this
regimen by structural and functional imaging, and explore its
effect upon disease-related symptoms (DRS). The secondary
objectives were to determine the progression-free survival (PFS)
and overall survival (OS) of patients treated with this regimen.
MATERIALS AND METHODS
Patients
Patients who met the following criteria were eligible: (1)
histological or cytological proven NSCLC with measurable disease;
(2) symptomatic locoregional disease; (3) unsuitable for radical
CRT – examples include: (i) disease extent technically unsuitable
for radical therapy, where the lung volumes encompassed by
radiotherapy plans for 60Gy were considered unacceptable, due to
the need to include N3 disease (supraclavicular or contralateral
mediastinal or hilar nodal involvement) or an excessive superior–
inferior disease extent, (ii) poor prognostic factors such as weight
loss in excess of 10%, (iii) concurrent medical illness or (iv) stage
IV disease with limited extra-thoracic spread, where it is judged
that the dominant competing risk for death is uncontrolled
locoregional disease; (4) no prior radiotherapy or chemotherapy;
(5) ECOG performance statusp1; (6) life expectancy in excess of 3
months; (7) adequate organ function – (i) hepatic: serum
bilirubinp1.0 ULN, AST and/or ALTp2.0 ULN, ALP and
GGTp2.5 ULN, if bone or liver involvement, AST or ALT, ALP
and GGTp5.0 ULN, (ii) bone marrow: haemoglobinX100gl
 1,
neutrophil countX1.5 10
9l
 1, platelet countX100 10
9l
 1, (iii)
renal: creatinine clearanceX55mlmin
 1 (using radioisotope renal
scan or derived from serum creatinine using the Cockcroft–Gault
formula); (8) age less than 75 years; (9) written informed consent.
The following patients were ineligible: (1) significant medical
conditions which were considered to compromise the planned
delivery of the chemotherapy and radiotherapy or be potentially
exacerbated by these modalities; (2) history of any other cancer
(except nonmelanoma skin cancer or carcinoma in situ of the
cervix) unless in complete remission and off all therapy for that
cancer for at least 5 years; (3) receiving treatment with another
investigational agent. Institutional ethics committee approval was
obtained.
Treatment plan
Chemoradiotherapy
1. Radiation therapy: All radiotherapy was administered using
6MeV linac, to a dose of 40Gy in 2Gy fractions, 5 per week for 4
weeks. The treatment plan was according to normal institutional
practice, namely: (1) AP-PA treatment fields, (2) planning target
volume (PTV)¼gross macroscopic disease (GTV)þ1cm, (3) dose
specified at the midplane on the central axis; however, regions
which may receive a greater dose by virtue of variation in patient
contour (e.g. neck) were compensated using beam attenuators or
mid-line shielding, to restrict the oesophageal dose to less than
42Gy. CT planning was not used routinely, unless there was
concern regarding dose heterogeneity related to changes in
contour, for example, proceeding from chest to neck, where the
dose to the oesophagus could potentially be excessive or where the
target volume required CT for accurate delineation. (4) Check
films in weeks 1 and 2 of radiotherapy. If week 2 film was
satisfactory, no further check films are required, otherwise repeat
weekly.
2. Concurrent chemotherapy: During the external radiation
therapy all patients received chemotherapy comprising of Cisplatin
intravenous (i.v.) weekly and Vinorelbine i.v. days 1, 8, 22. Day 15
Vinorelbine was excluded due to the expected cumulative
neutropenia from the prior doses.
The doses of each agent were escalated through six planned dose
levels (DLs). Vinorelbine was escalated from 15 to
30mgm
 2week
 1 and Cisplatin from 20 to 30mgm
 2week
 1.
All chemotherapy was given within 2h of the delivery of the
radiation fraction on that day. Premedication was standard. No
pre- or post-hydration was utilised.
3. Definition of dose-limiting toxicities (DLTs): These were based
on toxicities experienced during, and within, 2 weeks following
CRT, and are defined as follows: (1) grade 4 neutropenia
(ANCo0.5 10
9l
 1) of any duration; (2) grade 4 thrombocyto-
penia (platelet counto10 10
9l
 1) or grade 3 thrombocytopenia
(platelet count 10–49 10
9l
 1) with bleeding; (3) febrile neutro-
penia; (4) grade 3 or 4 nonhaematological toxicity (within or
outside the radiation field), including nausea and vomiting despite
adequate antinauseant therapy; (5) interruption of radiotherapy in
excess of 1 week; (6) chemotherapy omitted for 1 or more weeks;
(7) toxicity requiring one or more dose reductions during CRT.
4. Dose escalation schema: Three patients were planned to be
entered into each DL. If no DLTs were observed in these three
patients, the next DL was opened. If DLTs were observed in X2o f
three patients, then no further dose escalation took place. If DLTs
were observed in one of three patients, then three additional
patients (total of six patients) were accrued at this level. If DLTs
were observed in p1 of six patients, then the next DL was opened.
If DLTs were observed in X2 of six patients, no further dose
escalation took place.
The highest administered dose was defined as that DL in which
two or more of three or six patients had DLTs. The recommended
DL (one below the highest administered dose) reached was
expanded to a total of 15 patients to obtain further data concerning
acute and late toxicities and response.
5. Dose modifications during CRT: Radiotherapy, together with
chemotherapy, was suspended if the patient experienced grade 3 or
4 radiation-associated toxicities (e.g. oesophagus, lung, skin,
heart). RT only was recommenced once reactions had improved
to grade 1 or better within a maximum of 2 weeks.
During CRT, the chemotherapy doses were modified based on
the worse grade of toxicities. Treatment modification was in two
forms: either (a) permanent dose reductions or (b) treatment
deferral with the recommencement at a reduced dose on recovery,
that is, neutrophils X1.0 10
9l
 1 or platelets 450 10
9l
 1, and
nonhaematological toxicity to grade 1. Patients entered at DL 1
requiring more than one dose reduction or entered at higher DLs
requiring more than two dose reductions discontinued chemo-
therapy; however, the radiotherapy continued.
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sTreatment was stopped early due to either disease progression, a
greater than 2-week delay in radiotherapy delivery, unacceptable
toxicity, patient request or patient noncompliance with the
required investigations.
Consolidation chemotherapy At 4 weeks after completing CRT,
all patients were planned to receive two cycles of chemotherapy,
unless there was radiological progressive disease on restaging prior
to this time. The chemotherapy consisted of Cisplatin 80mgm
 2
i.v. day 1 and Vinorelbine 25mgm
 2 i.v. weekly by three, the
cycles were repeated every 28 days. The toxicities from these cycles
were not used to determine the DLTs for CRT. Premedication and
hydration regimens for Cisplatin and chemotherapy dose mod-
ifications were standard. On day 1 of each cycle, the following
parameters were required: ANCX1.5 10
9l
 1, platelet
countX100 10
9l
 1 and creatinine clearanceX55mlmin
 1, and
all nonhaematological toxicities resolved to at least grade 1. If these
were not achieved within 2 weeks, the patient ceased treatment.
Monitoring procedures and tests
At baseline (within 2 weeks of trial entry), patients had
performance status recorded, bloods taken for full blood
examination and differential and biochemistry (including serum
urea, electrolytes and creatinine, calcium, liver function tests
(bilirubin, AST/ALT, ALP, GGT)) and creatinine clearance
estimation (using radioisotope renal scan or derived from serum
creatinine using Cockcroft–Gault formula). Staging comprised of a
chest X-ray PA/lateral, CT scan of the chest and upper abdomen,
CT scan of the brain and bone scan if clinically indicated, FDG-
PET scan (optional, subject to availability), spirometry and the
assessment of DRS by the Lung Cancer Symptom Scale (LCSS)
(Hollen et al, 1993).
During treatment patients were reviewed weekly, with docu-
mentation of acute toxicities. Bloods were taken weekly as above,
except for haematology, which was performed twice weekly during
CRT. Creatinine clearance was estimated weekly during CRT and
on day 1 of each course of consolidation chemotherapy. DRS were
assessed weekly during CRT.
Tumour response (radiological and FDG-PET), spirometry and
completion of the LCSS were repeated at 3 weeks post-CRT and 4
weeks post-completion of all therapy. Patients were then reviewed
every 2 months for late radiation toxicities (RTOG/EORTC
criteria), and restaging, (until documented progression or earlier
if clinical suspicion) until death or loss to follow-up.
Statistical analysis
Criteria for the assessment of treatment outcomes and toxicities
Tumour response: Radiological response was assessed as above,
utilising the same methods as at baseline. The best overall
radiological response within and outside the radiation field was
documented using the WHO criteria (Miller et al, 1981).
Toxicities: Acute toxicities were assessed using the NCI Common
Toxicity Criteria (version 2.0, 30 April 1999). Late radiation
toxicities were assessed using the RTOG/EORTC criteria.
Statistical methods The worst grades of acute toxicities experi-
enced during CRT, which were considered to be definitely or
probably related to protocol treatment, were reported for all
patients by DL using descriptive statistics. The overall response
rate (complete (CR)þpartial responses (PR)) following CRT was
estimated as the percentage of all patients, and its 95% confidence
interval was estimated using the exact probabilities of the binomial
distribution.
Disease-related. symptoms were assessed by the LCSS (Hollen
et al, 1993). The patient subjective rating scale was used in these
analyses and the data analysed as per the published methodology
(Hollen et al, 1993). A Wilcoxon signed-rank test was used to find
the difference in symptom scores before and after radiotherapy
treatment. A two-sided Po0.05 was considered to be statistically
significant.
All patients who commenced treatment were included in the
analyses of PFS and OS. Patients were followed to a close-out date
of 29 September 2003. Progression-free survival time was
measured from the date of commencing protocol treatment to
the date of first progression (local, regional of distant) or death
without previous progression. Overall survival time was measured
from the date of commencing protocol treatment to the date of
death from any cause. The Kaplan–Meier method was used to
estimate OS and PFS, with censoring of survival times at the close-
out date. The Brookmeyer–Crowley method was used to estimate
95% confidence intervals for median survival times. The 95%
confidence intervals for the percentages surviving at particular
times were calculated using the logit transformation.
A potential follow-up time for each patient was defined as the
time from commencing protocol treatment to the close-out date,
unless the patient was lost to follow-up. A competing risks analysis
was used to estimate cumulative incidence rates for different types
of first progression.
RESULTS
Patients
In all, 24 patients were recruited from 30 June 2000 and 16
September 2003, from two oncology centres, across four DLs.
Patient demographics are summarised in Table 1. Males pre-
dominated, with over 63% of patients being over 60 years of age.
The majority, 22 patients (92%), had stage IIIB or limited stage IV
disease. Approximately 70% of patients had disease incorporated
within the field due to mainly N3 disease (supraclavicular or
contralateral hilar or mediastinal nodal involvement), while two
patients had less extensive disease, but with adverse clinical or
prognostic factors contraindicating radical therapy.
Treatment delivery
Chemoradiotherapy
1. Chemotherapy: A total of 24 patients were accrued across four
DLs of weekly Cisplatin plus Vinorelbine: DL 1 (15, 20mgm
 2,
respectively), three patients; DL 2 (20, 20mgm
 2), three patients;
DL 3 (25, 20mgm
 2), 15 patients; DL 4 (30, 20mgm
 2), three
patients.
Dose level 4 was identified as the highest administered dose and
hence DL 3, as discussed above, was expanded to a total sample of
15 patients.
Full dose delivery was achieved in DL 1 and 2, but dose
omissions were observed in DL 3 and 4, specifically on days 15 and
22. The planned day 15 Cisplatin treatment was omitted in six
patients due to the following reasons: grade 4 neutropenia in five
(two in DL 4 and three in DL 3) and chest infection in one patient
(DL 3). Vinorelbine was not planned to be administered on day 15.
On day 22, both drugs were omitted in two patients in DL 3, due to
grade 3 neutropenia and persistent chest infection, respectively.
At the recommended DL, DL 3, the relative dose intensity (ratio
of actual dose to planned dose) for the weekly Vinorelbine was
92% (range 66.7–100%) and for Cisplatin was 88.3%, (range 50–
100%).
2 Radiotherapy: The planned total dose of 40Gy was delivered to
23 or 96% of patients, with the remaining patient, receiving 30Gy
in 15 fractions, having refused to continue with treatment. In all,
19 or 79% of the patients completed the prescribed radiotherapy
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sover the planned 28 days (5 days per week, weeks 1–4). The
reasons for a break in the planned treatment of five patients were:
two patients with a febrile episode (nonfebrile neutropenia), one
patient unwell, one patient unknown and one patient with refusal
to continue.
3. Dose-limiting toxicities: These were prospectively defined and
assessed only during the CRT dose escalation component of the
treatment, as described above. The DLTs observed were haema-
tological, where, in DL 4, two of the three patient cohort developed
grade 4 neutropenia. Hence, DL 4 was determined to be the highest
administered dose and DL 3 was defined as the recommended dose
for expansion to 15 patients in total.
Consolidation chemotherapy Of the 24 patients entered, 20 had
cycle 1 and 16 patients had both cycles 1 and 2. Four patients had
not received the planned first courses of consolidation therapy due
to the following reasons: progressive disease (one patient),
persistent chest infection (one patient), withdrawal of consent
(one patient) and inadequate haematological recovery (one
patient). Of the 20 patients who planned to receive the second
course, four had not received therapy due to: persistent nausea and
vomiting (one patient), febrile neutropenia (one patient), acute
renal impairment (one patient) and unknown (one patient). The
dose intensity overall for Cisplatin on day 1 was 96.2% and the
Vinorelbine (days 1, 8, 15) was 73%.
Toxicity
The haematological and nonhaematological toxicities from day 1
of CRT to the commencement of the first course of consolidation
chemotherapy are detailed in Tables 2 and 3, respectively. The
concurrent therapy was well tolerated overall. There were four
patients who developed grade 4 neutropenia; however, only one
developed febrile neutropenia. A further patient developed a chest
infection. In terms of the nonhaematological toxicities, of note,
there were no reported cases of grade 3 or 4 radiation oesophagitis
or pulmonary toxicity.
In the 20 patients who proceeded onto consolidation chemo-
therapy, grade 4 neutropenia was observed in seven (35%)
patients, two patients each in DLs 2 and 4 and three in DL 3.
Febrile neutropenia was observed in two patients (10%), one each
in DL 1 and 3, respectively. Other toxicities included sensory
neuropathy, grade 2 in one patient in DL3, and grade 1 in two
patients, one each in DLs 1 and 4. Grade 3 renal impairment was
observed in one patient in DL3.
The following late radiation toxicities, according to the EORTC/
RTOG criteria, were observed: (i) oesophageal: grade 1, one
patient, DL1; grade 2, one patient, DL3; (ii) skin: grade 1, one
patient, DL2 and (iii) lung: grade 1, one patient, DL1; grade 3, two
patients, DL 1 and 3, respectively.
Spirometry was performed in patients at baseline (n¼24), at 3
weeks post-CRT (n¼18) and at the completion of all therapy
(n¼11). The mean FEV1.0 at each of these time points was: 70.9%
predicted (range 38–101%), 74.5 and 62%, respectively. The FVC
at each of these time points was 86.2% predicted (range 51–124%),
91.8 and 82%, respectively.
Response
The overall radiological response data following the completion of
all therapy (both within and outside the radiation field) are
summarised in Table 4. Of the 24 patients entered, 23 were
evaluable for response, with one patient refusing to continue
Table 1 Patient characteristics
Characteristics Number %
Sex
Male:female 14:10 58:42
Age
Median 65
Range 41–75
Histology
Squamous 8 33
Adenocarcinoma 8 33
Other 8 33
Stage
I (T2N0) 1 4
IIIA (T3N2) 1 4
IIIB (T1–3,N3 or T4,N0–3) 12 50
IV (T1–4,N0–3,M1) 10 42
Distribution of M1 sites (n¼10)
a
Bone 4 17
Lung (different lobe to primary) 3 12
Adrenal 2 8
Distant lymph node 2 8
Pericardium 1 4
Pleura 1 4
Disease anatomy in relation to radiation field
Disease entirely inside field 16 70
Disease inside/outside radiation field 8 30
Weight loss over prior 3 months
None 15 63
p10% 9 38
ECOG performance status
04 1 7
11 8 7 5
22 8
Presenting lung cancer symptoms as recorded by the LCSS (n¼20)
b
Patients with X4 symptoms 17 85
Dyspnoea 17 85
Haemoptysis 7 35
Cough 17 85
Pain 14 70
Fatigue 18 90
Anorexia 17 85
aPatients may have had more than one site of M1 disease.
bThose who had
symptoms X5mm in the symptom scale were considered as symptom occurrence.
Table 2 Haematological toxicities observed during concurrent chemor-
adiotherapy (NCI-CTC Version 2, 30 April 1999)
Dose levels
Toxicities
Worst
grade
1
(n¼3)
2
(n¼3)
3
(n¼15)
4
(n¼3)
Total
(%)
Leucocytes 3 0 0 4 3 7 (29)
4 0 0 2 0 2 (8)
Neutrophils 3 0 0 2 0 2 (8)
4 0 0 2 2 4 (17)
Platelets 3 0 0 0 0 0 (0)
4 0 0 0 0 0 (0)
Haemoglobin 3 0 0 0 0 0 (0)
4 0 0 0 0 0 (0)
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streatment during CRT. Thus, of these 23 patients, the overall
radiological response rate was 65% (15 of 23) (95% confidence
interval (CI): 34–77%), with CR and PR rates of 4% (one of 23)
and 61% (14 of 23), respectively. Stable disease was observed in
17% (four of 23), with progressive disease in two patients (9%),
one outside and one inside the radiation field.
The radiological response rate within the radiation filed is also
summarised in Table 4, with similar results as above. In all, 30% or
eight patients had sites of disease that were not incorporated
within the radiation field. Of these, a PR was observed in one
patient and two patients had progressed outside the radiation field.
Sites of relapse
The location of first progression is detailed in Table 5. Of the 24
patients entered, local control was observed in 18 patients;
however, regional nodal relapse (within or adjacent to the
radiation field) was observed in 12 patients, with half being
isolated without progression at other sites. Distant progression was
observed in 13 (54%) patients; in the majority of cases this was
isolated without local or regional involvement. One patient had
died without progression. The cumulative incidence of first
progression is shown in Figure 1. The cumulative incidence of
local–regional first progression at 6 and 12 months was 12.5 and
41.7%, respectively, and for distant progression (alone or with
locoregional progression) the risk was 29.2 and 45.8%, respec-
tively.
Survival parameters
Patients were followed up from commencing protocol treatment to
a close-out date of 29 September 2003. One patient was lost to
follow-up. The median potential follow-up time was 21.6 months
(range 12.4–38.9 months), with all patients having progressed or
died at the close-out date. The Kaplan–Meier PFS and OS survival
curves are shown in Figure 2A and B. The actuarial PFS was 6.1
months (95% CI 4.5–7.9 months), with the estimated PFS at 6 and
12 months being 54% (95% CI 35–73%) and 8% (95% CI 2–28%),
respectively.
The actuarial OS was 13.5 months (95% CI 10.4–438.9
months). The OS at 6, 12 and 24 months was 88% (95% CI 68–
96%), 58% (95% CI 38–76%) and 34% (95% CI 17–56%),
respectively.
Of the 24 patients, 12 were classified as stage IIIB and 10 stage
IV. The median OS for the stage IIIB and IV patients was 16.3 (95%
CI 10.4–438.9 months) and 12.4 months (95% CI 5.0–427.1
months), respectively. The OS difference between the stages was
not significant (P¼0.358).
DRS and QOL
Of the 24 patients entered, only 20 patients had LCSS data at
baseline and 19 patients at 3 weeks post-CRT. The major
Table 3 Nonhaematological toxicities observed during concurrent
chemoradiotherapy (NCI-CTC Version 2, 30 April 1999)
Dose levels
Toxicities
Worst
grade
1
(n¼3)
2
(n¼3)
3
(n¼15)
4
(n¼3)
Total
(%)
Febrile
neutropenia
3 0 0 1 0 1 (4)
Fever without
grade 3 or 4
neutropenia
3 0 0 1 0 1 (4)
Vomiting 2 0 0 2 0 2 (8)
Fatigue 3 0 1 2 0 3 (13)
Weight loss 2 0 1 0 0 1 (4)
Inner ear/
hearing
2 1 0 0 0 1 (4)
Renal
impairment
1 0 0 1 0 1 (4)
Radiation
dermatitis
2 1 0 4 1 6 (25)
Radiation
oesophagitis
2 1 1 5 1 8 (33)
Table 4 Radiological response following the completion of all therapies
Dose levels
Response parameters
(n¼23)
1
(n¼3)
2
(n¼3)
3
(n¼14)
4
(n¼3) No. (%)
Overall best response
Complete response 0 0 1 0 1 (4%)
Partial response 2 3 7 2 14 (61%)
Stable disease 0 0 4 0 4 (17%)
Progressive disease 1 0 0 1 2 (9%)
Not evaluable 0 0 2 0 2 (9%)
Best response in radiation field
Complete response 0 0 1 0 1 (4%)
Partial response 2 3 7 2 14 (61%)
Stable disease 0 0 4 0 4 (17%)
Progressive disease 0 0 0 1 1 (4%)
Not evaluable 1 0 2 0 3 (13%)
Table 5 The location of first progression
Location N %( n¼24)
Local
a 2 8.3
Regional
b 6 25.0
Distant
c 9 37.5
Local–regional 2 8.3
Regional–distant 2 8.3
Local–regional–distant 2 8.3
Death without progression 1 4.2
aPrimary lesion.
bRelapse in (a) nodal stations within the radiation field, that is,
involved hilar, mediastinal or supraclavicular nodes or (b) mediastinal or
supraclavicular nodes adjacent to the radiation field.
cM1 sites.
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spresenting symptoms are summarised in Table 1, with those due to
local disease, including cough, pain and dyspnoea, being recorded
by at least 70% of patients. Over 80% of patients had four or more
symptoms at baseline, with 30% having six symptoms.
As shown in Figure 3, the post-CRT LCSS evaluation found that
30–50% of patients had an improvement in loss of appetite, cough
and dyspnoea, with 37% of patients showing an improvement in
overall symptom distress. A decline in scores was observed in up
to 32% of patients subject to the parameters; for example, no
patient had a decline or worsening of haemoptysis, but for 32%
there was a deteriorating normal activity. A stabilisation of LCSS
scores post-CRT was observed in 39–90% of patients, subject to
the parameter.
Relative to baseline, at 3 weeks post-CRT, there was a
nonsignificant trend towards improvement in scores for loss of
appetite (P¼0.20), dyspnea (P¼0.13), haemoptysis (P¼0.14),
pain (P¼0.36), overall symptomatic distress (P¼0.19) and overall
QOL (P¼0.54) after CRT (Table 6). There was a statistically
significant improvement in cough (P¼0.02) following CRT. The
average LCSS score decreased after CRT (27.1 vs 21.2, P¼0.08).
DISCUSSION
Patients with unresectable NSCLC and good PS who are unable to
receive radical combined CRT may be treated initially with
chemotherapy alone or with HDPR if there are significant local
symptoms. The incremental benefit from the addition of
chemotherapy to HDPR has not been defined. It however
represents an important ground for investigation (Bogart, 2004),
given the benefits achieved by its incorporation within the radical
radiation setting.
The primary aim of this trial was therefore to identify a tolerable
regimen of weekly Cisplatin and Vinorelbine combined with HDPR
(40Gy) that could be subsequently compared to radiation alone in
a randomised trial. The eligibility criteria in this study represented
a heterogeneous group of patients, but all patients were at least
ECOG 1 and most were not suitable for radical radiotherapy due to
the extent of disease (i.e. 50% with stage IIIB and 42% stage IV
disease and 30% having disease outside the irradiated volume). All
patients were locally symptomatic, requiring palliation, with the
majority having multiple DRS at presentation.
Of the entire cohort, 20 patients were staged by FDG-PET. This
imaging mode has been shown by several studies to upstage
approximately 30% of patients being considered for radical
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Table 6 The descriptive statistics of the LCSS scores at baseline and at 3
weeks post CRT
Baseline (n¼20)
3 weeks after CRT
(n¼19)
Item
Mean
(s.d.)
Median
(range)
Mean
(s.d.)
Median
(range)
Loss of appetite 27.7 (24.5) 24 (0, 99) 23.1 (27.2) 9 (0, 91)
Fatigue
a 35.5 (27.8) 31 (0, 95) 33.8 (27.2) 27 (0, 85)
Cough
a 33.4 (27.9) 25 (0, 87) 16.7 (19.7) 12 (0, 83)
Dyspnea
a 38.9 (31.3) 33 (0, 93) 23.1 (25.0) 15 (0, 80)
Haemoptysis 4.3 (5.1) 2 (0, 18) 2.5 (2.9) 1 (0, 8)
Pain 19.0 (22.3) 11 (0, 89) 14.4 (18.1) 11 (0, 65)
Overall symptomatic
distress
31.5 (31.8) 19 (0, 93) 22.4 (22.6) 13 (0, 79)
Normal activity 26.7 (23.9) 18 (0, 97) 29.7 (30.9) 12 (0, 98)
Overall quality of life 26.7 (14.8) 18 (0, 85) 25.4 (25.8) 11 (0, 90)
Mean LCSS 27.1 (16.6) 28 (2, 62) 21.2 (15.6) 19 (1, 50)
aN¼18 at followup assessment.
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stherapy by the detection of unsuspected metastasis. It has also
been shown to provide a better correlation with survival vs
conventional staging (Dunagan et al, 2001; Kalff et al, 2001;
Hoekstra et al, 2003; MacManus et al, 2003). A retrospective study
from our institution has also demonstrated that OS correlated with
FDG-PET defined metastatic disease burden, for example, 12
months in patients with one metastatic site vs 5 months if greater
than one site (Hicks et al, 2001; MacManus et al, 2003). On the
other hand, the use of PET staging here may have led to selection
bias, identifying those patients with reduced disease burden
outside the chest and hence better OS relative to those staged by
standard imaging as used in older studies.
The selection of patients suitable for this novel combined
approach was rigorous and consistent. The inability to deliver
radical CRT either for technical (extent of thoracic disease or
presence of distant disease) or clinical reasons (medical comor-
bidities) was based on consensus following detailed discussions of
the patient’s case among the same cohort of medical specialists.
These included thoracic radiation and medical oncologists, as well
as the input of radiologists, nuclear and respiratory medicine
physicians within the same tertiary referral cancer centre.
The regimen as detailed was both tolerable and showed
promising activity. There was dose escalation of Vinorelbine and
Cisplatin during HDPR, and the toxicities observed here defined
DL 3 for evaluation in subsequent trials. The prespecified DLTs
were pragmatic and clinically relevant to the treatment of such
patients with a combined approach. The DLTs identified were as
expected haematological, that is, grade 4 neutropenia, but overall
there was only one episode of febrile neutropenia and no grade 3
radiation oesophagitis. Of note, there were no significant late
oesophageal toxicities or treatment-related deaths.
The overall dose intensity of chemotherapy during CRT was
approximately 90% and also in the recommended DL (DL 3), with
all but one patient having received the full radiation dose. The
consolidation therapy of two cycles of Cisplatin and Vinorelbine
was delivered to 16 of the 24 patients overall; the toxicities
observed were not unexpected for this regimen, being mainly
haematological in nature. The current role of consolidation
chemotherapy following either high-dose palliative or radical
CRT has not been established. Two phase II trials, one of which
was a three-arm randomised study, have suggested an improved
survival with the addition of consolidation chemotherapy to
radical CRT relative to CRT alone (Choy et al, 2002; Gandara et al,
2003). Within the limits imposed by a phase I trial design, the
regimen has demonstrated promising efficacy, with a overall
radiological response rate (in and out of field) of 65% (15/23)
comprising of CR in 4% (one) and PR in 61% (14).
In the literature, there have been few studies that have addressed
the issue of chemotherapy in combination with palliative radio-
therapy in patients with NSCLC. In contrast to this trial, these
studies have utilised hypofractionated radiation schedules with
differing chemotherapy regimens. The first assessed the combina-
tion of weekly Docetaxel (10–45mgm
 2week
 1) with 50Gy, 5Gy
per week in 26 patients with stage III/IV disease. The response rate
in 19 evaluable patients was 73.7%, with the remainder having
stable disease. No local recurrence was observed with this regimen.
The toxicities were mainly chemotherapy-related, but palliative
benefit in terms of symptom response was not recorded
(Schwarzenberger et al, 2004).
A further study evaluated 50 patients with stage IV disease
treated with Carboplatin (300mgm
 2, days 1 and 29) plus oral
Etoposide (50mgm
 2, days 1–29) and concurrent radiotherapy
28Gy, 14Gy fractions at one per week (days 1 and 8). The overall
response rate was 28% with a median survival of 7 months. Nearly
one-fifth of the patients had grade 3 oesophagitis and 9% had
grade 3 pulmonary toxicity. Approximately 60–75% had an
improvement in their local symptoms; however, a validated
symptom or QOL scale was not used (Jeremic et al, 1999).
A more recent phase I study in 29 patients evaluated two such
regimens as follows: (i) hypofractionated radiotherapy, 17Gy, 8.5-
Gy fractions at one per week, combined with Vinorelbine, from 20
to 30mgm
 2 on days 1 and 8 every 28 days, and (ii) 60Gy, 5-Gy
fractions at one per week, plus weekly Vinorelbine from 10 to
20mgm
 2, for 12 weeks. In the first regimen the DLTs were
haematological, with one treatment-related toxic death, and in the
second one patient suffered grade 3 oesophagitis and one had a
late toxic death due to pneumonitis. Response data were not
provided (Slivano et al, 2000).
It hence appears that the regimen reported here is possibly as
efficacious as the hypofractionated CRT schedules, albeit with the
absence of significant toxicities, most likely reflecting the reduced
fraction size. The more important question remaining is whether
the addition of chemotherapy to HDPR provides additional benefit
to HDPR alone or to chemotherapy alone in these patients.
It is usual for patients with stage IIIB and IV patients (making
up 92% of our cohort) to be treated with chemotherapy alone
rather than external beam therapy. In the majority of phase III
studies, stage IIIB contribute 10–40% (Frasci et al, 2000; Ranson
et al, 2000; Kelly et al, 2001; Scagliotti et al, 2002; Schiller et al,
2002) of patients and stage IV patients would vary considerably in
disease bulk outside the thorax (Frasci et al, 2000; Ranson et al,
2000; Scagliotti et al, 2002). Systemic therapy is associated with a
median survival ranging from 6 to 8 months. As discussed above,
the trial methodology and staging methods used in this study
would preclude a direct comparison to chemotherapy-alone trials.
However, local control is still relevant in patients treated with
chemotherapy alone, with up to 10–50% requiring local palliative
radiation. (Anderson et al, 2000; Ranson et al, 2000).
While considering the above limitations, it would be of interest
to compare the results reported here with those from randomised
trials of palliative radiation summarised in Table 7. These studies
are heterogenous in terms of the eligibility criteria, assessment of
symptomatic benefit, treatment and staging procedures, the latter
reflecting that some of these were reported in the 1980s. In
comparison to our own study, similar patient cohorts and
radiation schedules were assessed in the trials reported by the
RTOG (Simpson et al, 1985) and the MRC (Macbeth et al, 1996).
The overall radiological response and OS observed in the study
reported here are comparable, and in particular may approach
schedules with higher biological effective doses. However, it must
be stated that the OS may have been impacted upon by selection
bias generated by FDG-PET staging and also the influence of
subsequent modern chemotherapy on progression.
Similar observations may be inferred by comparing the relapse
patterns from this study and those of the reported trials. In this
study local progression was observed in 25% of patients, with
regional nodal relapse being observed in 42%, the majority being
isolated, perhaps indicating geographical misses or areas not
attaining full radiation dose. Subject to the variation in the
definition of relapse sites and imaging across studies, these results
appear promising relative to the reported randomised trials of
HDPR. In the RTOG study (Simpson et al, 1985) for the entire
cohort, distant and local relapses were reported in 52 and 59%,
respectively. Local relapse ranged from 49% for the 40-Gy split
course group to 67% for the 40-Gy continuous cohort (Simpson
et al, 1985). In the MRC study, the first site of definite/suspected
relapse was the primary site in 33% of the F2 and 38% of the F13
patients, and for distant sites 39% in both (Macbeth et al, 1996).
Patient LCSS was measured prior to commencement of
treatment, during and 3 weeks post-completion of CRT. Post-
CRT, there was a significant improvement in cough (P¼0.02), as
well as a nonsignificant trend towards improvement in the other
symptoms and parameters assessed. There was no decrement in
overall QOL despite the rather intense treatment. The palliative
benefits reported in our trial are consistent with the reported
literature subject to dose and fractionation. The level of benefit
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srelative to the these studies may have been underestimated due to
the short time interval from treatment completion to the final
assessment of symptom benefit (Simpson et al, 1985; Macbeth
et al, 1996; Sundstrom et al, 2004). In the MRC study (Macbeth
et al, 1996), symptom response was assessed by the Rotterdam
Symptom Checklist for the duration of the trial. The percent of
patients with palliation for cough by 1 vs 2 months post-treatment
was 36 vs 48%, respectively, with the other symptoms having
improved by a similar trend over this time. The benefit had
actually increased by an additional 14% of cases at 3 months
(Macbeth et al, 1996).
In conclusion, we have therefore defined a regimen for
weekly Cisplatin plus Vinorelbine combined with HDPR in
patients with NSCLC not suitable for radical CRT, but of
good performance status and requiring local palliation. The
regimen is both tolerable with an interesting level of efficacy in
terms of radiological and functional response, as well as palliative
benefit. The regimen will be evaluated further as part of a national
study.
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